Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Clinical Revenue and Reimbursement, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):524-532. doi: 10.1038/s41391-018-0056-7. Epub 2018 Jul 9.
The cornerstone of prostate cancer diagnosis remains the transrectal ultrasound-guided biopsy (TRUS-BX), which most frequently occurs in the office setting under local anesthesia. However, there are now other techniques of prostate biopsy aimed at improving outcomes such as patient comfort, significant cancer detection, and infectious complications. The purpose of the present study is to compare the cost and efficacy outcomes of five different approaches.
We compared the comprehensive costs of a random sample size of 20-30 cases from each of the following: (1) local anesthesia TRUS-BX (reference), (2) sedation TRUS-BX, (3) general anesthesia transperineal template biopsy (TP), (4) sedation MRI-TRUS fusion biopsy (FB), and (5) sedation in-bore MRI biopsy (IB-MRI). Cost categories included pre-procedure, anesthesia pharmacy and recovery, and the technical/professional costs from urology, radiology, and pathology services. For procedure outcomes, we compared the larger cohorts of TRUS-BX, TP, and FB in terms of indication, cancer yield, and downstream decision impact.
Compared with standard TRUS-BX, the total costs of sedation TRUS-BX, TP, FB, and IB-MRI increased significantly ×1.9 (90%), ×2.5 (153%), ×2.5 (150%), and ×2.2 (125%), respectively (p < 0.001). Although there was no statistical difference between the total costs of TP, FB, and IB-MRI, these costs were significantly higher than those of TRUS-BX under either local anesthesia or sedation (p < 0.05). The cost of TRUS-BX under sedation was significantly higher than that of TRUS-BX under local anesthesia (p < 0.001). Compared to TRUS-BX, more significant cancers were detected in FB (16% vs. 36%) and TP (16% vs. 34%) groups (p < 0.001).
Compared with standard TRUS-BX, the additions of imaging, sedation anesthesia, and transperineal template increase costs significantly, and can be considered along with known improvements in accuracy and side effects. Ongoing efforts to combine imaging and transperineal biopsy, especially in an outpatient/local anesthesia setting may lead to a higher cost/benefit.
前列腺癌诊断的基石仍然是经直肠超声引导活检(TRUS-BX),它最常在局麻下的办公室环境中进行。然而,现在有其他前列腺活检技术旨在改善患者舒适度、显著提高癌症检出率和感染并发症等方面的效果。本研究的目的是比较五种不同方法的成本和疗效结果。
我们比较了以下 20-30 例随机样本的综合成本:(1)局部麻醉 TRUS-BX(参考)、(2)镇静 TRUS-BX、(3)全身麻醉经会阴模板活检(TP)、(4)镇静 MRI-TRUS 融合活检(FB)和(5)镇静腔内 MRI 活检(IB-MRI)。成本类别包括术前、麻醉药和恢复以及泌尿科、放射科和病理科服务的技术/专业成本。对于手术结果,我们比较了 TRUS-BX、TP 和 FB 的更大队列,以确定适应症、癌症检出率和下游决策影响。
与标准 TRUS-BX 相比,镇静 TRUS-BX、TP、FB 和 IB-MRI 的总费用分别显著增加×1.9(90%)、×2.5(153%)、×2.5(150%)和×2.2(125%)(p<0.001)。尽管 TP、FB 和 IB-MRI 的总费用之间没有统计学差异,但这些费用明显高于局部麻醉或镇静下的 TRUS-BX(p<0.05)。镇静下 TRUS-BX 的成本明显高于局部麻醉下的 TRUS-BX(p<0.001)。与 TRUS-BX 相比,FB(16%比 36%)和 TP(16%比 34%)组的显著癌症检出率更高(p<0.001)。
与标准 TRUS-BX 相比,增加影像学、镇静麻醉和经会阴模板会显著增加成本,并且可以与准确性和副作用的已知改善一起考虑。目前正在努力将影像学和经会阴活检结合起来,特别是在门诊/局部麻醉环境中,可能会带来更高的成本效益。